GlassScriptPhysician profile
James Edward Fitzpatrick
NPI 1063459246
$5,445.06
in general payments reported to CMS, 2019-2025
11 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $50.40 · 2021: $230 · 2022: $2,370 · 2023: $53.72 · 2024: $1,787 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Travel and Lodging: $511 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.35 |
| Travel and Lodging | $510.65 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,086.82 | 2019-2024 | |
| Davol INC. | $426.89 | 2019-2022 | |
| Smith+Nephew, INC. | $361.88 | 2019-2025 | Collagenase Santyl, Regranex |
| C. R. Bard, INC. & Subsidiaries | $176.80 | 2019 | |
| Organogenesis INC. | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $89.52 | 2019-2023 | Bridion |
| Misonix INC | $87.52 | 2020-2021 | |
| Ethicon US, LLC | $54.75 | 2019-2025 | Vistaseal, Stratafix, Surgiflo Hemostatic Matrix |
| Sanara Medtech INC. | $23.10 | 2025 | Celleraterx |
| Becton, Dickinson and Company | $22.99 | 2019 | |
| Zimmer Biomet Holdings, INC. | $14.79 | 2025 | Rosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.